Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- HHS Secretary Kennedy’s diet advice is heavy on meat and light on scientific consensus
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- “This is not about protecting life”: Supreme Court overturn of Roe v. Wade threatens lives of cancer patients, doctors
- Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research - President’s budget request would cap indirect costs and fully fund all NIH research projects upfront
